Organogenesis Holdings Inc

ORGO remains in a sustained downtrend on both medium- and long-term horizons, trading below all key moving averages with no active bullish patterns. Medium-term bias is bearish given persistent lower highs and lows and resistance at the 21/50 EMA zone. Short-term execution readiness is confirmed by a failed rally into the EMAs and rejection at moving-average resistance. Sell Now is advised at these resistance levels into the ongoing downtrend.

• ↑Q2 revenue rose 18% QoQ to $42.8 M, indicating sales rebound.
• ↑Restructuring cuts 138 jobs to save ~$18 M annually.
• ↓Q2 revenue fell 58% YoY to $42.8 M; advanced wound care sales down 61%.